Ardelyx, Inc.

Equities

ARDX

US0396971071

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-19 pm EDT 5-day change 1st Jan Change
5.51 USD +0.36% Intraday chart for Ardelyx, Inc. -6.45% -11.13%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Ardelyx, Groups File Lawsuit Over Dialysis Payment System Coverage MT
Ardelyx sues US health department over kidney disease drug RE
HC Wainwright Adjusts Ardelyx's Price Target to $10 From $13, Keeps Buy Rating MT
Piper Sandler Downgrades Ardelyx to Neutral From Overweight, Cuts Price Target to $7 From $15; Shares Plunge MT
Wedbush Adjusts Ardelyx's Price Target to $11 From $15, Keeps Outperform Rating MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Ardelyx Opts Out of CMS Payment Adjustment for Xphozah; Shares Plunge Pre-Bell MT
Sector Update: Health Care MT
Ardelyx Opts Out of CMS Payment Adjustment for Xphozah MT
Transcript : Ardelyx, Inc. - Special Call
Ardelyx Chose Not To Apply To Include Xphozah In CMS End-Stage Renal Disease Prospective Payment System Transitional Drug Add-On Payment Adjustment RE
Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 2000 Value Index CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 3000 Value Index CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 2500 Value Index CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index CI
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell 3000E Value Index CI
Ardelyx Shares Fall; Chief Commercial Officer Resigns MT
Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer CI
Ardelyx Insider Sold Shares Worth $2,522,217, According to a Recent SEC Filing MT
Ardelyx Insider Sold Shares Worth $1,831,503, According to a Recent SEC Filing MT
Ardelyx Insider Sold Shares Worth $333,574, According to a Recent SEC Filing MT
Ardelyx Shares Rise After Q1 Beat MT
Wedbush Adjusts Ardelyx's Price Target to $15 From $14, Keeps Outperform Rating MT
Top Premarket Gainers MT
Chart Ardelyx, Inc.
More charts
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.51 USD
Average target price
10.94 USD
Spread / Average Target
+98.63%
Consensus
  1. Stock Market
  2. Equities
  3. ARDX Stock
  4. News Ardelyx, Inc.
  5. Earnings Flash (ARDX) ARDELYX Reports Q1 Revenue $46M, vs. Street Est of $36.4M